The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 339:114-115 July 9, 1998 Number 2
NextNext

Treatment of Chronic Hepatitis B Infection

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Lai, C.-L.
-PubMed Citation
In this issue of the Journal, Lai et al.1 report the results of a one-year trial of lamivudine, an oral nucleoside analogue, in patients with chronic hepatitis B infection. The 358 patients were randomly assigned to receive daily lamivudine (25 mg or 100 mg) or placebo orally for one year. The incidence of adverse events was similar in all groups and there were few serious adverse events. Histologic improvements, including a reduction in necroinflammatory activity and fibrosis, were demonstrated in the patients treated with lamivudine, as compared with those receiving placebo. The patients treated with 100 mg of lamivudine had . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.